• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿尔茨海默病。科学事务委员会报告。

Alzheimer disease. Report of the Council on Scientific Affairs.

作者信息

Guttman R, Altman R D, Nielsen N H

机构信息

Council on Scientific Affairs, American Medical Association, Chicago, Ill., USA.

出版信息

Arch Fam Med. 1999 Jul-Aug;8(4):347-53. doi: 10.1001/archfami.8.4.347.

DOI:10.1001/archfami.8.4.347
PMID:10418544
Abstract

Alzheimer disease (AD) takes a heavy economic, social, physical, and psychological toll on patients, families, and society. Because of the increasing life expectancy in the United States, AD is expected to afflict approximately 14 million people within the next few decades. There is currently no cure, only interventions that can temporarily ameliorate the profound cognitive losses and behavioral manifestations of the disorder. Community services are fragmented and underutilized. Physicians, in their traditional role as gatekeepers, can encourage more families to use supportive services. This article reviews the guidelines on the diagnosis and treatment of AD of the Agency for Health Care Policy and Research, the American Academy of Neurology, the Veterans Health Administration, and the American Psychiatric Association. Although these guidelines contain valuable information, they do not adequately address the role of the family physician and the need for continuity of care. Recommendations regarding AD from the Council on Scientific Affairs, which were adopted as American Medical Association policy in December 1997, are included in this article.

摘要

阿尔茨海默病(AD)给患者、家庭和社会带来了沉重的经济、社会、身体和心理负担。由于美国人均寿命不断延长,预计在未来几十年内,AD将折磨约1400万人。目前尚无治愈方法,只有一些干预措施能暂时缓解该疾病严重的认知衰退和行为表现。社区服务零散且未得到充分利用。医生作为传统的把关人,可以鼓励更多家庭使用支持性服务。本文回顾了医疗保健政策与研究机构、美国神经病学学会、退伍军人健康管理局以及美国精神病学协会关于AD诊断和治疗的指南。尽管这些指南包含了有价值的信息,但它们并未充分阐明家庭医生的作用以及持续护理的必要性。本文还纳入了科学事务委员会于1997年12月被采纳为美国医学协会政策的关于AD的建议。

相似文献

1
Alzheimer disease. Report of the Council on Scientific Affairs.阿尔茨海默病。科学事务委员会报告。
Arch Fam Med. 1999 Jul-Aug;8(4):347-53. doi: 10.1001/archfami.8.4.347.
2
Alzheimer's disease. AMA Council on Scientific Affairs Reference Committee D.阿尔茨海默病。美国医学协会科学事务委员会参考委员会D。
J Okla State Med Assoc. 1998 Aug;91(5):298-306.
3
Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society.阿尔茨海默病及相关疾病的诊断与治疗。美国老年精神病学协会、阿尔茨海默病协会及美国老年医学会的共识声明。
JAMA. 1997;278(16):1363-71.
4
Practical treatment strategies for patients with Alzheimer's disease.阿尔茨海默病患者的实用治疗策略。
J Fam Pract. 2007 Dec;56(12 Suppl New):S17-23.
5
2012 Alzheimer's disease facts and figures.2012 年阿尔茨海默病事实和数据。
Alzheimers Dement. 2012;8(2):131-68. doi: 10.1016/j.jalz.2012.02.001.
6
Policy versus practice: comparison of prescribing therapy and durable medical equipment in medical and educational settings.政策与实践:医疗和教育环境中处方治疗与耐用医疗设备的比较
Pediatrics. 2004 Nov;114(5):e612-25. doi: 10.1542/peds.2004-1063.
7
Family pediatrics: report of the Task Force on the Family.家庭儿科学:家庭问题特别工作组报告
Pediatrics. 2003 Jun;111(6 Pt 2):1541-71.
8
9
Physicians and family caregivers. A model for partnership. Council on Scientific Affairs, American Medical Association.
JAMA. 1993 Mar 10;269(10):1282-4.
10
White paper on expanding the role of pharmacists in caring for individuals with Alzheimer's disease: APhA Foundation Coordinating Council to Improve Collaboration in Supporting Patients with Alzheimer's Disease.关于扩大药剂师在照顾阿尔茨海默病患者中作用的白皮书:美国药剂师协会基金会协调委员会,旨在改善支持阿尔茨海默病患者方面的协作。
J Am Pharm Assoc (2003). 2008 Nov-Dec;48(6):715-21. doi: 10.1331/JAPhA.2008.08144.

引用本文的文献

1
Chitosan-Based Nanoparticles for Targeted Nasal Galantamine Delivery as a Promising Tool in Alzheimer's Disease Therapy.基于壳聚糖的纳米颗粒用于靶向鼻腔递送加兰他敏,作为阿尔茨海默病治疗的一种有前景的工具。
Pharmaceutics. 2023 Mar 3;15(3):829. doi: 10.3390/pharmaceutics15030829.
2
A network based method for analysis of lncRNA-disease associations and prediction of lncRNAs implicated in diseases.基于网络的 lncRNA 疾病关联分析方法及疾病相关 lncRNA 预测
PLoS One. 2014 Jan 31;9(1):e87797. doi: 10.1371/journal.pone.0087797. eCollection 2014.
3
Long-term safety and tolerability of rivastigmine in patients with Alzheimer's disease switched from donepezil: an open-label extension study.
从多奈哌齐转换而来的卡巴拉汀在阿尔茨海默病患者中的长期安全性和耐受性:一项开放标签扩展研究。
Prim Care Companion J Clin Psychiatry. 2008;10(5):363-7. doi: 10.4088/pcc.v10n0503.
4
Linkage and association study of late-onset Alzheimer disease families linked to 9p21.3.与9p21.3相关的晚发性阿尔茨海默病家族的连锁与关联研究。
Ann Hum Genet. 2008 Nov;72(Pt 6):725-31. doi: 10.1111/j.1469-1809.2008.00474.x. Epub 2008 Aug 28.
5
Galantamine: a pharmacoeconomic review of its use in Alzheimer's disease.加兰他敏:对其用于阿尔茨海默病的药物经济学综述
Pharmacoeconomics. 2002;20(13):919-42. doi: 10.2165/00019053-200220130-00005.
6
Fine mapping of the chromosome 12 late-onset Alzheimer disease locus: potential genetic and phenotypic heterogeneity.12号染色体迟发性阿尔茨海默病基因座的精细定位:潜在的遗传和表型异质性
Am J Hum Genet. 2000 Mar;66(3):922-32. doi: 10.1086/302828.